BRAIN and NERVE－神経研究の進歩75巻7号

2023年07月発行

特集 Antibody Update 2023　Part2 末梢編

重症筋無力症と自己抗体

著者： 鵜沢顕之¹

所属機関： ¹千葉大学大学院医学研究院脳神経内科学

ページ範囲：P.831 - P.835

文献概要

重症筋無力症は自己抗体が病態の中心にある代表的な自己抗体介在性免疫疾患である。重症筋無力症の病原性自己抗体としてAChR抗体，MuSK抗体，Lrp4抗体が知られているが，Lrp抗体に関しては疾患特異性などの観点から病原性自己抗体として十分確立しているとは言えない。これら自己抗体の神経筋接合部における標的，抗体陽性の意義，臨床像と治療，予後の差異などに関して概説する。

参考文献

1）Ohkawara B, Ito M, Ohno K: Secreted signaling molecules at the neuromuscular junction in physiology and pathology. Int J Mol Sci 22: 2455, 2021［doi: 10.3390/ijms22052455］

2）Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490, 2009

3）Suzuki S, Masuda M, Uzawa A, Nagane Y, Konno S, et al: Japan MG Registry: chronological surveys over 10 years. Clin Exp Neuroimmunol 14: 5-12, 2023

4）Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843-2854, 2006

5）Mori S, Kubo S, Akiyoshi T, Yamada S, Miyazaki T, et al: Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 180: 798-810, 2012

6）日本神経学会（監修）, 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン作成委員会（編）：重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン2022. 南江堂, 東京, 2022

7）Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Oda F, et al: Changes in serum complements and their regulators in generalized myasthenia gravis. Eur J Neurol 28: 314-322, 2021

8）Engel AG, Arahata K: The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505: 326-332, 1987

9）Obaid AH, Zografou C, Vadysirisack DD, Munro-Sheldon B, Fichtner ML, et al: Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 9: e1169, 2022［doi: 10.1212/NXI.0000000000001169］

10）Uzawa A, Suzuki S, Kuwabara S, Akamine H, Oonishi Y, et al: Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 94: 467-473, 2023

11）Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn R, et al; REGAIN Study Group: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16: 976-986, 2017

12）Vu T, Meisei A, Mantegazza R, Annane D, Katsuno M, et al; CHAMPION MG Study Group: Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 1: 2022［doi: 10.1056/EVIDoa2100066］

13）Howard JF Jr, Bril V, Vu T, Karam C, Peric S, et al; ADAPT Investigator Study Group: Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20: 526-553, 2021

14）Kojima Y, Uzawa A, Ozawa Y, Yasuda M, Onishi Y, et al: Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. J Neurol Neurosurg Psychiatry 92: 963-968, 2021

15）Morren J, Li Y: Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review. Muscle Nerve 58: 344-358, 2018

16）Kawakami Y, Ito M, Hirayama M, Sahashi K, Ohkawara B, et al: Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 77: 1819-1826, 2011

17）Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, et al: Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 14: 1029-1034, 2007

18）Triplett JD, Hardy TA, Riminton DS, Chu SYK, Reddel SW: Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: a marker of relapse? Muscle Nerve 60: 307-311, 2019

19）Higuchi O, Hamuro J, Motomura M, Yamanashi Y: Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422, 2011

20）Bacchi S, Kramer P, Chalk C: Autoantibodies to low-density lipoprotein receptor-related protein 4 in double seronegative myasthenia gravis: a systematic review. Can J Neurol Sci 45: 62-67, 2018

21）Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, et al: Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123: 5190-5202, 2013

22）Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, et al: LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol 1: 80-87, 2014